Avita Medical (ASX:AVH) said today that the FDA approved a supplement to the company’s investigational device exemption for its ReCell autologous cell harvesting device.
The approved treatment protocol for burn injuries has been simplified, according to the company, and the number of approved investigational sites has grown from eight to 15.
Get the full story at our sister site, Drug Delivery Business News.
The post FDA expands protocol for investigational ReCell burn injury device appeared first on MassDevice.
from MassDevice http://ift.tt/2wwEx6P
Cap comentari:
Publica un comentari a l'entrada